Drug Trial Radar · NCT04468971
REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia
Last checked: Nov 19, 2026Latest source record: Mar 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Sep 29, 2020
Primary completion
Oct 22, 2021
Study completion Oct 22, 2021
Sponsor
- Lead sponsor
- Cellenkos, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 13, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the safety and efficacy of CK0802 in treatment of patients with COVID-19 induced moderate-to-severe PNA-ARDS.
Conditions
- COVID19
- ARDS
Interventions
CK0802Biological
Cryopreserved, off the shelf, cord blood derived T regulatory cells
PlaceboDrug
Expicient
Primary outcomes
What the sponsor says the trial is designed to measure.
- Regimen related ≥ grade 3 toxicity within 48 hours of first infusionTime frame: 48 hours
- 28-day treatment success, defined as S28Time frame: 28 days
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Johns Hopkins Hospital
Baltimore, Maryland
Columbia University
New York, New York
University of North Carolina
Chapel Hill, North Carolina
Wake Forest University
Winston-Salem, North Carolina
Baylor College of Medicine, St Luke's Hospital
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.